Skip to main content
Hybrigenics SA logo

Hybrigenics SA — Investor Relations & Filings

Ticker · ALHYG ISIN · FR0004153930 LEI · 9695003KQD0XMJYDX764 PA Professional, scientific and technical activities
Open in API
Filings indexed 145 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country FR France
Listing PA ALHYG

About Hybrigenics SA

https://www.hybrigenics-services.com/

Hybrigenics Services is a specialized provider of technologies for studying molecular interactions. Its core offering is the ULTImate Y2H™ platform, a comprehensive Yeast Two-Hybrid system used to discover protein-protein interactions, as well as interactions with DNA, RNA, and small molecules. This technology is applied to drug discovery for target deconvolution and identifying molecular glues. A second key service is the Hybribody platform, which leverages a proprietary synthetic library for the custom selection, validation, and optimization of single-domain antibodies (VHHs/Nanobodies). The company serves clients in fundamental research, pharmaceutical R&D, and agroscience.

Recent filings

Filing Released Lang Actions
WEBINAIRE ATON DESTINÉ AUX ACTIONNAIRES ET INVESTISSEURS INDIVIDUELS MARDI 12 MAI 2026 À 18H00
Regulatory Filings
2026-05-07 French
RESULTATS ANNUELS 2025
Earnings Release Classification · 92% confidence The document is a press release summarizing the consolidated full-year 2025 financial results (revenue, EBITDA, net loss, balance sheet), along with strategic commentary and outlook. It explicitly states that the full annual report will be available later, indicating this is the initial announcement of the periodical (annual) financial results rather than the full annual report itself. Therefore, it fits the definition of an Earnings Release (ER). FY 2025
2026-04-28 French
B CELL DESIGN : COMMENT UNE INNOVATION BREVETÉE RÉPOND À UNE PÉNURIE MONDIALE DE RÉACTIFS DIAGNOSTIQUES
Regulatory Filings Classification · 75% confidence The document is a corporate press release (“communiqué de presse”) by Groupe Aton highlighting a portfolio subsidiary’s technology; it contains no financial results, no meeting materials, no regulatory stress test, no dividends, no capital raising or share transactions, and no formal report attachments. It is not an investor slide deck but a general announcement. Therefore, it falls under the fallback category for miscellaneous regulatory announcements.
2026-04-23 French
AMÉLIORER LE TAUX DE SUCCÈS DES ESSAIS CLINIQUES : UN ENJEU STRUCTURANT POUR LA RetD PHARMACEUTIQUE AU COEUR DE LA STRATÉGIE DU GROUPE ATON
Regulatory Filings Classification · 75% confidence The document is a corporate press release describing Aton’s strategic focus on improving clinical trial success rates and outlining upcoming communications (e.g., next report on Bcell Design and the date for annual 2025 results). It does not present financial results itself (not an earnings release), nor is it a management report or investor slide deck; it is a general business update and announcement. There is no detailed financial data or regulatory filing form specified. This fits the fallback category for miscellaneous regulatory announcements that don’t fit other precise types.
2026-04-01 French
ATON: UPDATE ON THE ACTIVITIES OF ITS SUBSIDIARY INOVIEM SCIENTIFIC
Regulatory Filings Classification · 95% confidence The document is a corporate press release providing an operational update on a subsidiary (Inoviem Scientific). It does not contain financial statements, audit reports, or specific regulatory filings like a 10-K or proxy statement. Since it is a general corporate announcement regarding business activities and strategy that does not fit into more specific categories like M&A or dividend notices, it falls under the general regulatory announcement category.
2026-03-11 English
ATON : POINT D'AVANCEMENT SUR L'ACTIVITÉ DE LA FILIALE INOVIEM SCIENTIFIC
Regulatory Filings Classification · 90% confidence The document is a press release issued by Aton regarding the operational progress of its subsidiary, Inoviem Scientific. It provides a business update on the subsidiary's activities, technology, and strategic positioning. It does not constitute a formal financial report, a regulatory filing, or a specific corporate action announcement (like dividends or M&A). As it is a general corporate update on business operations, it falls under the 'Regulatory Filings' (RNS) category as a catch-all for miscellaneous corporate announcements that do not fit into more specific categories.
2026-03-11 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.